PINNA, ANNALISA
 Distribuzione geografica
Continente #
EU - Europa 57.623
NA - Nord America 2.092
AS - Asia 343
SA - Sud America 4
Continente sconosciuto - Info sul continente non disponibili 3
AF - Africa 2
Totale 60.067
Nazione #
IT - Italia 57.121
US - Stati Uniti d'America 2.082
CN - Cina 242
UA - Ucraina 172
SE - Svezia 120
DE - Germania 64
GB - Regno Unito 54
SG - Singapore 47
FI - Finlandia 42
VN - Vietnam 22
FR - Francia 14
BE - Belgio 13
KR - Corea 10
CA - Canada 9
IL - Israele 8
HK - Hong Kong 5
IN - India 5
CZ - Repubblica Ceca 4
ES - Italia 4
NL - Olanda 4
RU - Federazione Russa 4
BR - Brasile 3
EU - Europa 3
PL - Polonia 3
CH - Svizzera 2
TH - Thailandia 2
CL - Cile 1
HR - Croazia 1
JP - Giappone 1
LB - Libano 1
MA - Marocco 1
MU - Mauritius 1
MX - Messico 1
PT - Portogallo 1
Totale 60.067
Città #
Cagliari 56.095
Uta 897
Fairfield 250
Chandler 238
Woodbridge 237
Ann Arbor 150
Ashburn 149
Wilmington 112
Seattle 111
Houston 96
Nyköping 96
Cambridge 91
Boardman 82
Jacksonville 81
Dearborn 71
New York 55
Shanghai 51
Beijing 37
Nanjing 37
Santa Clara 30
Singapore 30
Boston 26
Dong Ket 22
Helsinki 16
San Diego 14
Brussels 13
Los Angeles 11
Nanchang 10
Rome 10
Sassari 10
Seoul 10
Shenyang 10
Falls Church 9
Guangzhou 9
Hebei 9
Toronto 8
Milan 7
Redwood City 7
Beersheba 6
Chicago 6
Jiaxing 6
Kunming 6
Mountain View 6
Oristano 6
Padova 6
Hong Kong 5
Jinan 5
London 5
Munich 5
Norwalk 5
Pune 5
Grottammare 4
Sestu 4
Tianjin 4
Washington 4
Zhengzhou 4
Cracow 3
Essen 3
Florence 3
Hangzhou 3
Hefei 3
Kilburn 3
Monopoli 3
Orange 3
Prescot 3
Atlanta 2
Auburn Hills 2
Baltimore 2
Bangkok 2
Bolzano 2
Camerino 2
Chengdu 2
Clifton 2
Gonnosfanadiga 2
Indiana 2
Madrid 2
Monza 2
Nuoro 2
Piscataway 2
Shaoxing 2
Taizhou 2
Verona 2
Wuhan 2
Xian 2
České Budějovice 2
Aci Catena 1
Acton 1
Ashdod 1
Baotou 1
Baratili San Pietro 1
Bay Springs 1
Benxi 1
Borås 1
Brno 1
Changchun 1
Changsha 1
Chiswick 1
Chizhou 1
Dübendorf 1
Fuzhou 1
Totale 59.371
Nome #
Pharmacological characterization of 50-kHz ultrasonic vocalizations in rats: comparison of the effects of different psychoactive drugs and relevance in drug-induced reward 3.537
Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease 3.429
Dopaminergic neurodegeneration in a rat model of long-term hyperglycemia: preferential degeneration of the nigrostriatal motor pathway 2.903
Protective Agents in Parkinson's Disease: Caffeine and Adenosine A2A Receptor Antagonists 2.801
Role of adenosine A2A receptors in motor control: relevance to Parkinson’s disease and dyskinesia 2.663
Late-onset Parkinsonism in NFκB/c-Rel-deficient mice 2.613
Symptomatic and Neuroprotective Effects of A2A Receptor Antagonists in Parkinson’s Disease 2.556
Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease 2.521
Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates l-DOPA-induced rotational behavior in a rodent model of Parkinson's disease 2.429
Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease 2.408
Lack of Rhes Increases MDMA-Induced Neuroinflammation and Dopamine Neuron Degeneration: Role of Gender and Age 2.342
The Small GTP-Binding Protein Rhes Influences Nigrostriatal-Dependent Motor Behavior During Aging 2.279
L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: Biochemical and behavioral studies 2.224
A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A2A receptor antagonists 2.204
A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug 2.009
Farmaci antiparkinsoniani ed attivi in altri disturbi motori 1.740
Behavioral, neurochemical, and electrophysiological changes in an early spontaneous mouse model of nigrostriatal degeneration 1.714
Caffeine consumption and changes in the function of dopaminergic transmission: evidence of a hyperdopaminergic state in rats subchronically treated with caffeine 1.697
Pharmacological therapy of Parkinson's disease: current options and new avenues 1.695
null 1.651
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat 1.555
Antiparkinsonian actions and interactions of adenosine antagonists 1.540
Acute perinatal asphyxia impairs non-spatial memory and alters motor coordination in adult male rats 1.128
Adenosine A2A receptor antagonist treatment of Parkinson’s disease 1.085
Adenosine A2A receptor antagonists and Parkinson’s disease: state of the art and future directions 1.067
null 1.012
null 967
Protective Agents in Parkinson’s Disease: Caffeine and Adenosine A2A Receptor Antagonists 805
null 801
Fos expression induced by olanzapine and risperidone in the central extended amygdala 705
Influence of Age and Genetic Background on Ethanol Intake and Behavioral Response Following Ethanol Consumption and During Abstinence in a Model of Alcohol Abuse 580
Characterization of Nasco grape pomace-loaded nutriosomes and their neuroprotective effects in the MPTP mouse model of Parkinson’s disease 566
null 410
Farmaci antiparkinsoniani ed attivi in altri disturbi motori 405
Subchronic-intermittent caffeine amplifies the motor effects of amphetamine in rats 185
Extract from Nasco pomace loaded in nutriosomes exerts anti-inflammatory effects in the MPTP mouse model of Parkinson's disease 22
Totale 60.248
Categoria #
all - tutte 69.774
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 69.774


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20206.476 0 0 0 0 0 3.308 1.720 315 234 321 188 390
2020/202115.804 484 586 697 5.147 3.419 1.543 1.062 739 290 790 614 433
2021/20223.056 317 232 151 142 220 225 284 189 218 351 323 404
2022/20234.735 455 676 566 405 420 425 236 285 314 333 414 206
2023/20244.061 199 201 148 258 399 665 659 300 172 282 339 439
2024/20254.295 730 945 849 883 440 448 0 0 0 0 0 0
Totale 60.248